RTB101 + everolimus
RTB101 + everolimus has been studied in 1 paper since 2021: 1 trial in people. The newest paper, May 6, 2021: “Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials”.
1 paper studies it1 findingUpdated
See all 1 papers on RTB101 + everolimus
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“RTB101 10 mg twice daily and RTB101 10 mg in combination with everolimus 0·1 mg once daily were not associated with a significant reduction in the incidence of laboratory-confirmed RTIs as compared with placebo (data not shown).”
- 1 lab in 1 country
- Funders: National Institute on Aging and 1 more
- 1 of 1 finding with company ties
- Human trial1
Studies in people
1 study gave RTB101 + everolimus to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on laboratory-confirmed respiratory tract infections | Randomized trial16 weeks | 1,500 peopleaged at least 65 yearsAdults aged at least 65 years | The lancet. Healthy longevity, May 6, 2021 |
What did studies of RTB101 + everolimus find?
1Studies of RTB101 + everolimus measured one outcome, laboratory-confirmed respiratory tract infections.
Laboratory-confirmed respiratory tract infections
no changein humans1
1 study
Laboratory-confirmed respiratory tract infections
no changein humans1
RTB101 + everolimus showed no clear effect on laboratory-confirmed respiratory tract infections in humans.
“RTB101 10 mg twice daily and RTB101 10 mg in combination with everolimus 0·1 mg once daily were not associated with a significant reduction in the incidence of laboratory-confirmed RTIs as compared with placebo (data not shown).”
Human trial10 mg plus everolimus 0·1 mg once daily16 weeks
The lancet. Healthy longevity